Epilepsy in neuronal ceroid lipofuscinoses

Abstract The neuronal ceroid lipofuscinoses (NCL) are a group of genetic lysosomal storage diseases characterized by dementia, epilepsy, motor deterioration and mostly also visual loss through retinal degeneration. As a group, they represent one of the most frequent etiologies of dementia in young persons. The present classification of the NCL disorders is based on the different genes involved and on the age at clinical onset, which can be anytime between the infantile and young adult age. We describe typical clinical pictures that may be caused by NCL types in the different age groups and an economic strategy for their diagnosis. While experimental therapies aiming to stop disease progression are being developed, palliative therapies may be disease-specific and can bring significant relief. This applies particularly to the therapy of the frequently drug-resistant epilepsy in NCL.

[1]  J. Østergaard,et al.  Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease) , 2014, Seizure.

[2]  Zarrin Ansari.  Levetiracetam: Pharmacological properties, safety and efficacy in the pediatric population with epilepsy , 2014, Journal of Pediatric Neurology.

[3]  C. Lavoie,et al.  Topology and Membrane Anchoring of the Lysosomal Storage Disease‐Related Protein CLN5 , 2013, Human mutation.

[4]  R. Crystal,et al.  Advances in the treatment of neuronal ceroid lipofuscinosis , 2013 .

[5]  H. Goebel,et al.  Human pathology in NCL. , 2013, Biochimica et biophysica acta.

[6]  J. Mink,et al.  NCL diseases - clinical perspectives. , 2013, Biochimica et biophysica acta.

[7]  K. Sims,et al.  Neuronal Ceroid Lipofuscinosis: Impact of Recent Genetic Advances and Expansion of the Clinicopathologic Spectrum , 2013, Current Neurology and Neuroscience Reports.

[8]  F. Andermann,et al.  Recurrent mutations in DNAJC5 cause autosomal dominant Kufs disease , 2013, Clinical genetics.

[9]  Katherine R. Smith,et al.  Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. , 2013, Human molecular genetics.

[10]  E. Bertini,et al.  Molecular epidemiology of childhood neuronal ceroid-lipofuscinosis in Italy , 2013, Orphanet Journal of Rare Diseases.

[11]  I. Scheffer,et al.  Is the ketogenic diet effective in specific epilepsy syndromes? , 2012, Epilepsy Research.

[12]  Katherine R. Smith,et al.  Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. , 2012, American journal of human genetics.

[13]  S. Cotman,et al.  The juvenile Batten disease protein, CLN3, and its role in regulating anterograde and retrograde post-Golgi trafficking , 2012, Clinical lipidology.

[14]  Katherine R. Smith,et al.  Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6. , 2011, American journal of human genetics.

[15]  A. Varma,et al.  Adult neuronal ceroid lipofuscinosis caused by deficiency in palmitoyl protein thioesterase 1 , 2007, Neurology.

[16]  P. Saftig,et al.  Cathepsin D deficiency is associated with a human neurodegenerative disorder. , 2006, American journal of human genetics.

[17]  A. Lehesjoki,et al.  Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. , 2006, Brain : a journal of neurology.

[18]  Z. Lukacs,et al.  Rapid and simple assay for the determination of tripeptidyl peptidase and palmitoyl protein thioesterase activities in dried blood spots. , 2003, Clinical chemistry.

[19]  H. Goebel,et al.  Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. , 2002, American journal of medical genetics.

[20]  S. Hofmann,et al.  Neuronal ceroid lipofuscinoses caused by defects in soluble lysosomal enzymes (CLN1 and CLN2). , 2002, Current molecular medicine.

[21]  E. Kirveskari,et al.  Epilepsy and Antiepileptic Drug Therapy in Juvenile Neuronal Ceroid Lipofuscinosis , 2000, Epilepsia.

[22]  Se Mole,et al.  NCL nomenclature and classification , 2011 .

[23]  T. Streichert,et al.  Analysis of Potential Biomarkers and Modifier Genes Affecting the Clinical Course of CLN3 Disease , 2011, Molecular medicine.

[24]  L. Thorne,et al.  Novel mutation and the first prenatal screening of cathepsin D deficiency (CLN10) , 2008, Acta Neuropathologica.

[25]  D. Palmer,et al.  The Neuronal Ceroid Lipofuscinoses (Batten Disease) , 1996 .